serena williams promoting glp-1 Opens Up About Using In Her Weight Loss Journey What Serena Williams' GLP-1 Story

Retatrutide drives the deep metabolic effect, including the glucagon-mediated bump in energy expenditure that sets it apart from older incretin drugs

Finn, MD, section chief of Obesity Medicine at the Dartmouth Health Walter and Carole Young Center for Digestive Health

Recent studies have demonstrated that a medication commonly prescribed for type 2 diabetes and obesity, glucagon-like peptide-1 receptor agonists (GLP-1RA), plays a role in facilitating retinal neuroprotection, which, in turn, may prevent glaucoma development and progression

Research into dual-mechanism protocols is emerging, with some studies suggesting complementary effects when agents target different appetite-control pathways

Post-pandemic screen time persistence compared to pre-2020 levels

Its good news, says Wendy E